This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Posvar, E. L. Articles by Sedman, A. J. Search for Related Content PubMed PubMed Citation Articles by Posvar, E. L. Articles by Sedman, A. J. Social Bookmarking                         What's this?

ACE Inhibitors in the Elderly

Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan

Allen J. Sedman

Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan

As the population with hypertension becomes older, it is important to determine the properties of angiotensin-converting enzyme (ACE) inhibitors in the elderly. The pharmacokinetics and efficacy of captopril, enalapril, and a new once-daily ACE inhibitor, quinapril for the treatment of hypertension in young and elderly patients are reviewed, and the safety profiles of these agents in young and elderly patients are discussed. Although the safely profile of all three drugs is very favorable, quinapril tended to be better tolerated by patients of all ages in comparative clinical trials.

Angiology, Vol. 42, No. 5, 387-396 (1991)
DOI: 10.1177/000331979104200506


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?